{
  "id": 12942261,
  "title": "XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout",
  "url": "https://urgent.news/2026/10/08/xortx-outlines-anticipated-health-canada-clinical-trial-application",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T20:04:36.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/xortx-outlines-anticipated-health-canada-clinical-trial-application-for-xrx-026-for-gout"
  },
  "original_language": "en",
  "account": null,
  "summary": "● Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}